No mention here yet, but Lonza setting itself up well. This little company has THE future...monoclonal antibodies and is partnering up with Lonza. Check the ENZC posting for details. Simply amazing and Lonza is going to be part of it.
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
I
Insider Call: Lonza partnering with Enzolytics... Joint PR coming next week.
ENZC is just $0.20... Worth $10++ EOY 2022.
o
Durham, NC-based Precision BioSciences (DTIL) has filed a prospectus for a $100M IPO. The biotech develops gene therapies for human diseases and sustainable food and agricultural solutions based on its ARCUS protein engineering platform which reprograms the DNA recognition properties of a natural genome-editing enzyme called I-Crel, adding that the approach is different from better-known CRISPR/Cas9 [the technology used by Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP)]. A Phase 1/2a clinical trial evaluating a gene-edited allogeneic CAR T candidate targeting CD18 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) patients should launch next quarter. The company believes its product is the first allogeneic CAR T for NHL. It also believes that its one-step engineering process will be cost- effective at scale and will overcome many of the challenges limiting the field thus far.
D
So why is this $33 BILLIONS company trading on OTC market? It's not like FNMA / FMCC who had been taken control by govn't.
d
My comment was from when E Warren was grilling Fauci, Hann, Redfield at vaccine hearing if they owned stocks in the companies. They all said no. Then she grilled about manufacturing companies of vaccines ... and mentioned Moderna and Lonza....
I guess she didn’t look at CTLT , TMO, EBS and WST as other tertiary vaccine plays for manufacturing or syringe components etc
D
Stayed tuned over here. Capricor Therapeutic’s is in a partnership with Lonza. Go check out CAPR message board and see what could be in the pipeline for Lonza.
W
It's absolutely official -- Lonza will have incredible production and it helps the world == the beginning of the end of the pandemic --- FDA approval!
o
Merry Christmas.
T
Sure hope Lonza is ready to manufacture when Mesoblasts remestemcel-l trial ends early due to overwhelming efficacy for severe ARDS caused by covid19.
http://dd.report/?s=LZAGF has an alert for $LZAGF. Did anyone happen to see it as well? Looking for some good positive information from the company! "rht" Day trading trading stocks.
DD Report | Due Diligence Reports
dd.report
C
any details from the call? hints at use of the massive revenue increase? maybe a very special div?
o
SGMO will hit big on Monday. great results in hemophilia A. Ah yes!
D
Lonza affiliate Neptune has just received it’s license to produce extract and sell cannabis oils and distillates from The Canadian government Lonza and Neptune are no ready to “rock and roll”!
m
Finally catching up on production from Moderna
d
I guess I am the only one here ....
W
It's official now --- Lonza will be partnering with Moderna to manufacture the COVID Vaccine as soon a the FDA approves!!!! Very bullish!
F
Here because of ALT.
A
lol. I'm in. with you now
d
Thanks for mentioning Lonza who is working w MRNA , Pocahontas...
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
ENZC is just $0.20... Worth $10++ EOY 2022.
The biotech develops gene therapies for human diseases and sustainable food and agricultural solutions based on its ARCUS protein engineering platform which reprograms the DNA recognition properties of a natural genome-editing enzyme called I-Crel, adding that the approach is different from better-known CRISPR/Cas9 [the technology used by Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP)].
A Phase 1/2a clinical trial evaluating a gene-edited allogeneic CAR T candidate targeting CD18 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) patients should launch next quarter. The company believes its product is the first allogeneic CAR T for NHL. It also believes that its one-step engineering process will be cost- effective at scale and will overcome many of the challenges limiting the field thus far.
I guess she didn’t look at CTLT , TMO, EBS and WST as other tertiary vaccine plays for manufacturing or syringe components etc
Coincidentally Lonza puts up a video about this...
https://www.lonza.com/news-and-media/a-view-on-podcast